Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer

Pancreatic cancer does not respond to a single-agent imatinib therapy. Consequently, multimodality treatments are contemplated. Published data indicate that in colorectal cancer, imatinib and radioimmunotherapy synergize to delay tumor growth. In pancreatic cancer, the tumor response is additive. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Abe, Michio, Kortylewicz, Zbigniew P., Enke, Charles A., Mack, Elizabeth, Baranowska-Kortylewicz, Janina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757429/
https://www.ncbi.nlm.nih.gov/pubmed/24212821
http://dx.doi.org/10.3390/cancers3022501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757429/
https://www.ncbi.nlm.nih.gov/pubmed/24212821
http://dx.doi.org/10.3390/cancers3022501

Ejemplares similares